MacroGenics, Inc. (NASDAQ: MGNX) Skyrockets 130% After Releasing Positive Results from the Phase 3 Clinical Study of Margetuximab
MacroGenics, Inc. (NASDAQ: MGNX) is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment ...
